Genor Biopharma Holdings
Genor Biopharma Holdings, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative therapies in the biotechnology sector. Founded in 2010, Genor has rapidly established itself as a key player in the development of monoclonal antibodies and biosimilars, focusing on oncology and autoimmune diseases. With a robust pipeline of products, Genor's unique approach combines advanced biomanufacturing techniques with a commitment to quality, setting it apart in a competitive market. The company has achieved significant milestones, including successful collaborations and regulatory approvals, which underscore its position as a trusted provider of cutting-edge biopharmaceutical solutions. As it continues to expand its operational reach across Asia and beyond, Genor Biopharma Holdings remains dedicated to improving patient outcomes through innovative science and technology.
DitchCarbon Score
How does Genor Biopharma Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genor Biopharma Holdings's score of 5 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genor Biopharma Holdings's reported carbon emissions
In 2023, Genor Biopharma Holdings reported total carbon emissions of approximately 2,487,160 kg CO2e, comprising 19,820 kg CO2e from Scope 1 and 2,467,340 kg CO2e from Scope 2 emissions. This represents a significant reduction from 2022, where emissions totalled about 6,191,480 kg CO2e, with Scope 1 emissions at 17,950 kg CO2e and Scope 2 emissions at 6,173,530 kg CO2e. In 2021, the company recorded total emissions of approximately 7,948,570 kg CO2e, with Scope 1 emissions at 20,510 kg CO2e and Scope 2 emissions at 7,928,420 kg CO2e. This indicates a downward trend in emissions over the past two years, showcasing Genor Biopharma's commitment to reducing its carbon footprint. Despite these reductions, there are currently no publicly disclosed reduction targets or climate pledges from Genor Biopharma Holdings. The company continues to focus on improving its energy consumption intensity, which was reported at 27.33 in 2023, down from 30.52 in 2022. This reflects ongoing efforts to enhance operational efficiency and sustainability within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 20,510 | 00,000 | 00,000 |
| Scope 2 | 7,928,420 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genor Biopharma Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
